AtriCure fleshes out afib portfolio with Estech buy
This article was originally published in Clinica
Executive Summary
AtriCure is bulking up its atrial fibrillation treatment portfolio with the acquisition of surgical ablation specialist Endoscopic Technologies (Estech). The deal, which is expected to close “in the next several weeks”, is worth up to $60m; it consists of an upfront payment of 2.1 million Atricure shares ($34m) and up to $26m of revenue-based milestone payments.